Teva shares down 13% following FDA approval of generic Copaxone
October 04, 2017 at 10:35 AM EDT
With litigation still pending, Teva said a launch of the product 'should be considered at-risk.'
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.